• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by AnaptysBio Inc.

    8/8/25 5:10:13 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001187333
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ANAPTYSBIO, INC.
    SEC File Number
    001-37985
    Address of Issuer
    10770 Wateridge Circle, Suite 210
    San Diego
    CALIFORNIA
    92121
    Phone
    (858) 362-6295
    Name of Person for Whose Account the Securities are To Be Sold
    HOLLINGS C RENTON
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    10231200712.782799696308/08/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common08/08/2025Stock Option ExerciseIssuerCheckbox not checked1023108/08/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    HOLLINGS C RENTON
    10770 Wateridge Circle, Suite 210
    San Diego � CA � 92121
    Common07/02/202520925493189.70
    HOLLINGS C RENTON
    10770 Wateridge Circle, Suite 210
    San Diego � CA � 92121
    Common06/18/2025301572269.55

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/08/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/14/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Hollings Renton

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ANAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANAB

    DatePrice TargetRatingAnalyst
    10/13/2025$78.00Overweight
    Barclays
    6/4/2025$38.00Neutral → Buy
    H.C. Wainwright
    2/4/2025$25.00Outperform
    Wolfe Research
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    12/2/2024Buy → Neutral
    BTIG Research
    7/22/2024$55.00Buy
    H.C. Wainwright
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    4/16/2024$47.00Outperform
    Leerink Partners
    More analyst ratings

    $ANAB
    SEC Filings

    View All

    SEC Form 10-Q filed by AnaptysBio Inc.

    10-Q - ANAPTYSBIO, INC (0001370053) (Filer)

    11/4/25 4:19:08 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ANAPTYSBIO, INC (0001370053) (Filer)

    11/4/25 4:17:12 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ANAPTYSBIO, INC (0001370053) (Filer)

    10/14/25 4:33:51 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    1/2/25 6:17:02 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    8/16/24 12:04:31 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

    Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025Phase 2b data for rosnilimab in rheumatoid arthritis featured as late-breaking oral presentation at ACR Convergence 2025Phase 1b initiated in celiac disease for ANB033, a CD122 antagonist; top-line Phase 1b data anticipated in Q4 2026GSK announced strong commercial performance for Jemperli, growing >16% quarter-over-quarter to $303 million in Q3 2025 and $785 million YTD 2025Anaptys anticipates accruing a one-time $75 million commercial sales milestone in Q4 2025 from GS

    11/4/25 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys Announces Participation in November Investor Conferences

    SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen Immunology & Inflammation Summit, Virtual Format – Fireside chatDate and Time – Wednesday, Nov. 12, 2025 at 8:00am ET Guggenheim 2nd Annual Healthcare Innovation Conference, Boston, MA Format – Fireside chat and 1x1 investor meetingsDate and Time – Wednesday, Nov. 12, 2025 at 11:30am ET Stifel 2025

    11/4/25 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

    New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKsNew data confirm durable clinical benefit across multiple higher-order response measures, including CDAI LDA and DAS28 LDA, after Week 28 for at least three months off drugUpdated safety data through Week 38 demonstrate rosnilimab was well-tolerated with no treatment-related serious adverse events and no malignancies in rosnilimab-treated patients SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on de

    10/29/25 9:15:00 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF LEGAL OFFICER Loumeau Eric J exercised 5,000 shares at a strike of $14.02 and sold $238,960 worth of shares (8,240 units at $29.00), decreasing direct ownership by 26% to 9,088 units (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    10/1/25 4:00:20 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orwin John A converted options into 1,300 shares, increasing direct ownership by 14% to 10,665 units (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    9/17/25 4:02:23 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Renton Hollings exercised 10,231 shares at a strike of $6.93 and sold $200,714 worth of shares (10,231 units at $19.62) (SEC Form 4)

    4 - ANAPTYSBIO, INC (0001370053) (Issuer)

    8/12/25 4:02:46 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on AnaptysBio with a new price target

    Barclays initiated coverage of AnaptysBio with a rating of Overweight and set a new price target of $78.00

    10/13/25 8:51:16 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded AnaptysBio from Neutral to Buy and set a new price target of $38.00

    6/4/25 7:31:04 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on AnaptysBio with a new price target

    Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00

    2/4/25 6:58:43 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 4:00:05 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

    SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

    11/14/24 9:24:47 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

    SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

    8/16/24 12:07:11 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Financials

    Live finance-specific insights

    View All

    Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

    Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101Company to host a conference call with investors today at 4:30pm ET/1:30pm PT SAN DIEGO, Sept. 29

    9/29/25 4:05:49 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

    Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b

    5/11/23 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANAB
    Leadership Updates

    Live Leadership Updates

    View All

    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

    SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

    4/17/25 7:00:00 AM ET
    $ANAB
    $DSGN
    $PSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services

    Actym Therapeutics Appoints Thomas Smart as CEO

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    4/24/24 9:00:00 AM ET
    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

    After more than 15 years serving on AnaptysBio's Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. "We are excited to welcome John to Anaptys' Board of Directors as chairman. With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO a

    9/18/23 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care